C25006 (R/R)

C25006 (R/R)

A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma


Study Treatments

Brentuximab vedotin IV on day 1 (21-day cycle; max 16 cycles)


Inclusion criteria


Exclusion criteria


Participating sites

Link